BEIJING--(BUSINESS WIRE)--Oct. 27, 2005--Sinovac Biotech Ltd. (AMEX:SVA), a leading Chinese biotechnology company in vaccine development and marketing, has announced that the State Food and Drug Administration (SFDA) issued a GMP (Good Manufacturing Practices) certificate for Sinovac's proprietary influenza flu vaccine, Anflu(TM). The GMP certificate is the final approval required to sell Anflu(TM) vaccine in China (PRC).
